Navigation Links
Vanda Pharmaceuticals to Present at Natixis Bleichroeder's Hidden Gems Conference
Date:10/3/2007

Presentation Will be Webcast Live and Archived on Company's Web Site

ROCKVILLE, Md., Oct. 3 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda President and CEO will deliver a corporate presentation on Monday, October 8, 2007, at 3:15 p.m. Eastern Time.

The presentation will take place as part of the Natixis Bleichroeder Hidden Gems Conference at The Carlton, New York. Dr. Polymeropoulos' remarks will be available live on the Vanda Web site, where it also will be archived for 30 days.

To access the presentation, log on to http://www.vandapharma.com and click on the Presentations option in the Investor Relations section. Please connect to the web site several minutes prior to the start of the live presentation to ensure adequate time for any software download that may be necessary.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness that is in a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com .


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 05, 2016 , ... An essential tool for researching and ... Canadian provinces is now available from the International Association of Industrial Accident Boards ... report, Workers’ Compensation Laws as of January 1, 2016, is a ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... enrichment program serving families of greater Dubuque, IA. The current campaign fundraises for ... honorably discharged veterans. Donations to Veteran’s Freedom Center may now be made here: ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Dr. Benjamin Stong ... non-surgical hair loss treatment. Dr. Stong is double board certified and the only ... for the treatment of hair loss. Non-surgical therapies such as stem cells can be ...
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs ... on the eve of National Nurses Week (May 6-12). Currently, HireNurses is ... With their enrollment into the Talent Tech Lab Virtual Incubation program, they will dramatically ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... available for iOS and Android devices. VisualDx is the first point of ... diagnostic support across general medicine. The system speeds diagnosis, therapy decisions and ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... May 5, 2016 ... addition of the  "Europe Thrombocythemia Market ...  report to their offering.  ... , ,The latest research Europe Thrombocythemia ... 2016, provides comprehensive insights into Thrombocythemia ...
(Date:5/4/2016)... New York , May 4, 2016 ... by Transparency Market Research entitled "Brain Computer Interface Market - ... 2016 - 2024," the  global brain computer interface (BCI) market ... by 2024. The market is estimated to expand at ... from 2016 to 2024. A BCI device ...
(Date:5/4/2016)... WASHINGTON D.C. , May 4, 2016 /PRNewswire/ ... its member companies concluded a series of free ... training in global requirements for Good ... part of quality assurance which ensures that products are ... by the marketing authorization (MA) or product specification. Only ...
Breaking Medicine Technology: